CSTONE PHARMA-B (02616) to Present CS2015 (OX40L/TSLP Bispecific Antibody) at ACAAI 2025

Stock News09-15

CSTONE PHARMA-B (02616) announced that CS2015, an OX40L/TSLP bispecific antibody from the company's autoimmune and inflammatory disease pipeline, has been selected for presentation at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The presentation will be delivered in the format of "electronic poster presentation plus on-site oral presentation." The conference will be held in Orlando, USA, from November 6-10.

CS2015 is a potential first-in-class/best-in-class bispecific antibody that simultaneously targets OX40L and TSLP. Through dual inhibition of key regulatory factors mediating Th2-driven inflammatory responses, it offers a novel therapeutic strategy for type 2 inflammatory diseases including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and other related conditions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115952695?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115952695","market":"nz","top_or_hot":-1,"title":"CSTONE PHARMA-B (02616) to Present CS2015 (OX40L/TSLP Bispecific Antibody) at ACAAI 2025","media":"Stock News","content":"<p>CSTONE PHARMA-B (02616) announced that CS2015, an OX40L/TSLP bispecific antibody from the company's autoimmune and inflammatory disease pipeline, has been selected for presentation at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The presentation will be delivered in the format of \"electronic poster presentation plus on-site oral presentation.\" The conference will be held in Orlando, USA, from November 6-10.</p>\n<p>CS2015 is a potential first-in-class/best-in-class bispecific antibody that simultaneously targets OX40L and TSLP. Through dual inhibition of key regulatory factors mediating Th2-driven inflammatory responses, it offers a novel therapeutic strategy for type 2 inflammatory diseases including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and other related conditions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSTONE PHARMA-B (02616) to Present CS2015 (OX40L/TSLP Bispecific Antibody) at ACAAI 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSTONE PHARMA-B (02616) to Present CS2015 (OX40L/TSLP Bispecific Antibody) at ACAAI 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-15 08:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSTONE PHARMA-B (02616) announced that CS2015, an OX40L/TSLP bispecific antibody from the company's autoimmune and inflammatory disease pipeline, has been selected for presentation at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The presentation will be delivered in the format of \"electronic poster presentation plus on-site oral presentation.\" The conference will be held in Orlando, USA, from November 6-10.</p>\n<p>CS2015 is a potential first-in-class/best-in-class bispecific antibody that simultaneously targets OX40L and TSLP. Through dual inhibition of key regulatory factors mediating Th2-driven inflammatory responses, it offers a novel therapeutic strategy for type 2 inflammatory diseases including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and other related conditions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"","article_id":"1115952695","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115952695","pubTimestamp":1757894656,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSTONE PHARMA-B (02616) announced that CS2015, an OX40L/TSLP bispecific antibody from the company's autoimmune and inflammatory disease pipeline, has been selected for presentation at the 2025 Annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B","BK1161":"生物科技","BK1574":"生物医药B类股","TSLP":"TSLA收益溢价策略ETF-Kurv"},"translate_title":"基石药业-B(02616)将在ACAAI 2025上展示CS2015（OX40L/TSLP双特异性抗体）","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1,"TSLP":1},"content_text":"CSTONE PHARMA-B (02616) announced that CS2015, an OX40L/TSLP bispecific antibody from the company's autoimmune and inflammatory disease pipeline, has been selected for presentation at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The presentation will be delivered in the format of \"electronic poster presentation plus on-site oral presentation.\" The conference will be held in Orlando, USA, from November 6-10.\nCS2015 is a potential first-in-class/best-in-class bispecific antibody that simultaneously targets OX40L and TSLP. Through dual inhibition of key regulatory factors mediating Th2-driven inflammatory responses, it offers a novel therapeutic strategy for type 2 inflammatory diseases including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and other related conditions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115952695","isCrawlerRequest":true}